240 related articles for article (PubMed ID: 25568217)
1. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Kröpelin TF; de Zeeuw D; Andress DL; Bijlsma MJ; Persson F; Parving HH; Heerspink HJ
Clin J Am Soc Nephrol; 2015 Mar; 10(3):410-6. PubMed ID: 25568217
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
[TBL] [Abstract][Full Text] [Related]
4. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
de Zeeuw D; Coll B; Andress D; Brennan JJ; Tang H; Houser M; Correa-Rotter R; Kohan D; Lambers Heerspink HJ; Makino H; Perkovic V; Pritchett Y; Remuzzi G; Tobe SW; Toto R; Viberti G; Parving HH
J Am Soc Nephrol; 2014 May; 25(5):1083-93. PubMed ID: 24722445
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
[TBL] [Abstract][Full Text] [Related]
6. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Andersen S; Jacobsen P; Tarnow L; Rossing P; Juhl TR; Parving HH
Nephrol Dial Transplant; 2003 Feb; 18(2):293-7. PubMed ID: 12543883
[TBL] [Abstract][Full Text] [Related]
7. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Parving HH;
Diabetes Care; 2010 Nov; 33(11):2304-9. PubMed ID: 20693353
[TBL] [Abstract][Full Text] [Related]
8. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2018 Jun; 20(6):1369-1376. PubMed ID: 29405626
[TBL] [Abstract][Full Text] [Related]
9. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
Boels MG; Avramut MC; Koudijs A; Dane MJ; Lee DH; van der Vlag J; Koster AJ; van Zonneveld AJ; van Faassen E; Gröne HJ; van den Berg BM; Rabelink TJ
Diabetes; 2016 Aug; 65(8):2429-39. PubMed ID: 27207530
[TBL] [Abstract][Full Text] [Related]
10. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
[TBL] [Abstract][Full Text] [Related]
11. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
[TBL] [Abstract][Full Text] [Related]
12. Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Heerspink HJ; Makino H; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Davis JW; Idler K; Kohan DE; Liu M; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2017 Apr; 19(4):545-552. PubMed ID: 27981738
[TBL] [Abstract][Full Text] [Related]
13. Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease.
Kröpelin TF; de Zeeuw D; Remuzzi G; Bilous R; Parving HH; Heerspink HJ
J Am Soc Nephrol; 2016 Nov; 27(11):3405-3412. PubMed ID: 27056294
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Parving HH
Clin J Am Soc Nephrol; 2011 May; 6(5):1025-31. PubMed ID: 21350110
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034
[TBL] [Abstract][Full Text] [Related]
16. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Lim SC; Koh AF; Goh SK; Chua CL; Heng BL; Subramaniam T; Sum CF
Diabetes Obes Metab; 2007 Jul; 9(4):477-82. PubMed ID: 17587389
[TBL] [Abstract][Full Text] [Related]
18. Paricalcitol for reduction of albuminuria in diabetes.
Kassimatis T
Lancet; 2011 Feb; 377(9766):635, author reply 636-7. PubMed ID: 21334524
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Delea TE; Sofrygin O; Palmer JL; Lau H; Munk VC; Sung J; Charney A; Parving HH; Sullivan SD
J Am Soc Nephrol; 2009 Oct; 20(10):2205-13. PubMed ID: 19762496
[TBL] [Abstract][Full Text] [Related]
20. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
